BCACP Gastrointestinal Disorders Management

Question 1

A patient is diagnosed with Helicobacter pylori-associated peptic ulcer disease. He has no penicillin allergy and has not previously received clarithromycin. Which regimen is considered first-line eradication therapy in areas with known clarithromycin resistance rates below 15%?

Accepted Answer

Clarithromycin triple therapy: PPI + clarithromycin + amoxicillin for 14 days

Answer

Clarithromycin-based triple therapy (PPI + clarithromycin + amoxicillin) for 14 days remains first-line in regions where clarithromycin resistance is less than 15% and the patient has no prior macrolide exposure. The ACG 2017 guidelines support this regimen in those circumstances. Bismuth quadruple therapy is preferred in areas of high clarithromycin resistance or in patients with prior macrolide exposure. Sequential therapy is an alternative with similar efficacy.

Question 2

A patient with gastroesophageal reflux disease (GERD) has had an inadequate response to lifestyle modifications. According to a step-up approach, which therapy should be tried FIRST before escalating to a proton pump inhibitor (PPI)?

Accepted Answer

H2 receptor antagonist (H2RA) taken as needed or regularly

Answer

The step-up approach to GERD management begins with lifestyle modifications, then antacids or H2 receptor antagonists (H2RAs) for mild or intermittent symptoms before advancing to PPIs for moderate-to-severe or frequent symptoms. H2RAs (e.g., famotidine) are appropriate as a step between antacids and PPIs. Sucralfate is used primarily for peptic ulcer disease, not GERD. Metoclopramide has a limited and cautious role due to neurological adverse effects.

Question 3

A patient with Crohn's disease involving the ileum is in remission on azathioprine monotherapy. Which biologic agent would be most appropriate to ADD for a patient with moderate-to-severe disease who fails to maintain remission on an immunomodulator alone?

Accepted Answer

Infliximab (anti-TNF-alpha)

Answer

Anti-TNF agents (infliximab, adalimumab) are the most established and guideline-preferred first-line biologic therapy for moderate-to-severe Crohn's disease, often combined with an immunomodulator (combo therapy reduces immunogenicity). Vedolizumab and ustekinumab are effective alternatives, particularly for patients who fail or cannot tolerate anti-TNF agents, but infliximab has the most robust long-term efficacy and safety data as an initial biologic in Crohn's disease.

Question 4

A patient taking a PPI for long-term GERD management asks about potential risks associated with chronic PPI use. Which of the following is the MOST well-established adverse effect of long-term PPI therapy?

Accepted Answer

Hypomagnesemia

Answer

Hypomagnesemia is a well-established and FDA-labeling-recognized adverse effect of long-term PPI use, particularly after more than one year of therapy. PPIs impair intestinal magnesium absorption. Other recognized long-term risks include increased risk of C. difficile infection, community-acquired pneumonia, vitamin B12 deficiency, and bone fractures. Hepatocellular carcinoma and pulmonary fibrosis are not established PPI adverse effects. Type 2 diabetes association is observational with unclear causality.

Question 5

A 35-year-old patient with irritable bowel syndrome with predominant constipation (IBS-C) has failed dietary fiber supplementation and osmotic laxatives. Which FDA-approved pharmacological agent is indicated specifically for IBS-C?

Accepted Answer

Linaclotide

Answer

Linaclotide (Linzess) is FDA-approved for IBS-C and chronic idiopathic constipation. It is a guanylate cyclase-C agonist that increases intestinal fluid secretion and accelerates transit. Alosetron is approved for severe IBS-D (diarrhea-predominant) in women only. Rifaximin is approved for IBS-D. Eluxadoline is approved for IBS-D.

BCACP - Board Certified Ambulatory Care Pharmacist Exam Practice Test

BCACP - Board Certified Ambulatory Care Pharmacist Exam Practice Test

BCACP Gastrointestinal Disorders Management